| First Author | Sim H | Year | 2020 |
| Journal | Int J Mol Sci | Volume | 21 |
| Issue | 10 | PubMed ID | 32422864 |
| Mgi Jnum | J:302660 | Mgi Id | MGI:6509405 |
| Doi | 10.3390/ijms21103455 | Citation | Sim H, et al. (2020) Iroquois Homeobox Protein 2 Identified as a Potential Biomarker for Parkinson's Disease. Int J Mol Sci 21(10):3455 |
| abstractText | The diagnosis of Parkinson's disease (PD) is initiated after the occurrence of motor symptoms, such as resting tremors, rigidity, and bradykinesia. According to previous reports, non-motor symptoms, notably gastrointestinal dysfunction, could potentially be early biomarkers in PD patients as such symptoms occur earlier than motor symptoms. However, connecting PD to the intestine is methodologically challenging. Thus, we generated in vitro human intestinal organoids from PD patients and ex vivo mouse small intestinal organoids from aged transgenic mice. Both intestinal organoids (IOs) contained the human LRRK2 G2019S mutation, which is the most frequent genetic cause of familial and sporadic PD. By conducting comprehensive genomic comparisons with these two types of IOs, we determined that a particular gene, namely, Iroquois homeobox protein 2 (IRX2), showed PD-related expression patterns not only in human pluripotent stem cell (PSC)-derived neuroectodermal spheres but also in human PSC-derived neuronal cells containing dopaminergic neurons. We expected that our approach of using various cell types presented a novel technical method for studying the effects of multi-organs in PD pathophysiology as well as for the development of diagnostic markers for PD. |
